Dolca Thomas - Net Worth and Insider Trading

Dolca Thomas Net Worth

The estimated net worth of Dolca Thomas is at least $586,591 dollars as of 2024-05-02. Dolca Thomas is the Director of Chinook Therapeutics Inc and owns about 10,000 shares of Chinook Therapeutics Inc (KDNY) stock worth over $403,900. Dolca Thomas is also the Chief Medical Officer of Principia Biopharma Inc and owns about 1,826 shares of Principia Biopharma Inc (PRNB) stock worth over $182,691. Details can be seen in Dolca Thomas's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Dolca Thomas has not made any transactions after 2022-09-02 and currently still holds the listed stock(s).

Transaction Summary of Dolca Thomas

To

Dolca Thomas Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Dolca Thomas owns 5 companies in total, including Aduro Biotech Inc (ADRO) , Principia Biopharma Inc (PRNB) , and Chinook Therapeutics Inc (KDNY) among others .

Click here to see the complete history of Dolca Thomas’s form 4 insider trades.

Insider Ownership Summary of Dolca Thomas

Ticker Comapny Transaction Date Type of Owner
ADRO Aduro Biotech Inc 2020-10-06 director
PRNB Principia Biopharma Inc 2020-09-28 Chief Medical Officer
KDNY Chinook Therapeutics Inc 2022-09-02 director
2021-01-11 Chief Medical Officer
2023-07-31 director

Dolca Thomas Latest Holdings Summary

Dolca Thomas currently owns a total of 2 stocks. Among these stocks, Dolca Thomas owns 10,000 shares of Chinook Therapeutics Inc (KDNY) as of September 2, 2022, with a value of $403,900 and a weighting of 68.86%. Dolca Thomas also owns 1,826 shares of Principia Biopharma Inc (PRNB) as of August 18, 2020, with a value of $182,691 and a weighting of 31.14%.

Latest Holdings of Dolca Thomas

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KDNY Chinook Therapeutics Inc 2022-09-02 10,000 40.39 403,900
PRNB Principia Biopharma Inc 2020-08-18 1,826 100.05 182,691

Holding Weightings of Dolca Thomas


Dolca Thomas Form 4 Trading Tracker

According to the SEC Form 4 filings, Dolca Thomas has made a total of 1 transactions in Chinook Therapeutics Inc (KDNY) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Chinook Therapeutics Inc is the acquisition of 10,000 shares on September 2, 2022, which cost Dolca Thomas around $212,200.

According to the SEC Form 4 filings, Dolca Thomas has made a total of 3 transactions in Principia Biopharma Inc (PRNB) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Principia Biopharma Inc is the sale of 15,000 shares on August 18, 2020, which brought Dolca Thomas around $2 Million.

Insider Trading History of Dolca Thomas

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Dolca Thomas Trading Performance

GuruFocus tracks the stock performance after each of Dolca Thomas's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Dolca Thomas is 11.03%. GuruFocus also compares Dolca Thomas's trading performance to market benchmark return within the same time period. The performance of stocks bought by Dolca Thomas within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Dolca Thomas's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Dolca Thomas

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -7.35
Relative Return to S&P 500(%) 1.28

Dolca Thomas Ownership Network

Ownership Network List of Dolca Thomas

No Data

Ownership Network Relation of Dolca Thomas


Dolca Thomas Owned Company Details

What does Aduro Biotech Inc do?

Who are the key executives at Aduro Biotech Inc?

Dolca Thomas is the director of Aduro Biotech Inc. Other key executives at Aduro Biotech Inc include director & President & CEO Eric Dobmeier , 10 percent owner Versant Voyageurs I, L.p. , and 10 percent owner Versant Voyageurs I Parallel, L.p. .

Aduro Biotech Inc (ADRO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aduro Biotech Inc (ADRO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aduro Biotech Inc (ADRO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aduro Biotech Inc (ADRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aduro Biotech Inc Insider Transactions

No Available Data

Dolca Thomas Mailing Address

Above is the net worth, insider trading, and ownership report for Dolca Thomas. You might contact Dolca Thomas via mailing address: C/o Principia Biopharma Inc., 220 E. Grand Avenue, South San Francisco Ca 94080.

Discussions on Dolca Thomas

No discussions yet.